Next-Gen Obesity Drugs

Eli Lilly and Novo Nordisk Rivalry Drives the Next Wave of Obesity Drugs

Eli Lilly & Co. demonstrated record weight loss in a study at a conference in Milan, Italy, a day before its rival, Novo Nordisk A/S, held a free Andrea Bocelli concert in the city's cathedral with a massive advertising screen and a Lilly-sponsored dance crew. The company's results have raised the bar for treating people with obesity and diabetes, raising the bar. Meanwhile, Novoso released data on existing blockbusters like Ozempic and CagriSema, which have mixed records in clinical trials.